Search results: Sage Journals

Free accessReview articleFirst published April, 2011

Salvage therapy for relapsed or refractory acute myeloid leukemia

James K. Mangan, Selina M. Luger

Therapeutic Advances in Hematology

Available accessReview articleFirst published July, 2020

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients

Daniel R Reed, Jeremy M Sen, Eric J Pierce [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2025

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Yu Zhang, Zhao Yin, Zurong Yao [...]

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2022

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Silvia Park, Daehun Kwag, Tong Yoon Kim [...]

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2022

Simultaneous therapy-related acute myeloid leukemia and relapse/refractory multiple myeloma: a therapeutic dilemma

Dewi Nurmaya Spree, Farhan Rafiuddin Jamaluddin, Suria Abd Aziz [...]

Proceedings of Singapore Healthcare

Open accessReview articleFirst published 2020

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

Serena Chew, Melissa C. Mackey, Elias Jabbour

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2026

Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial

Juan Ren, Tongxin Zhang, Yuqi Wang [...]

Cell Transplantation

Free accessReview articleFirst published June, 2017

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape

Valeriy Sedov, Robert K. Stuart

Therapeutic Advances in Hematology

Free accessResearch articleFirst published November, 2018

Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens

Wenfeng Luo, Huilan Yu, Xingli Zou [...]

Cancer Biomarkers

Open accessResearch articleFirst published 2023

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia

Uday Kulkarni, Arun Kumar Arunachalam, Hamenth Kumar Palani [...]

Cell Transplantation

Free accessReview articleFirst published April, 2011

Salvage therapy for relapsed or refractory acute myeloid leukemia

James K. Mangan, Selina M. Luger

Therapeutic Advances in Hematology

Available accessReview articleFirst published July, 2020

Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients

Daniel R Reed, Jeremy M Sen, Eric J Pierce [...]

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2025

Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia

Yu Zhang, Zhao Yin, Zurong Yao [...]

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2022

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)

Silvia Park, Daehun Kwag, Tong Yoon Kim [...]

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2022

Simultaneous therapy-related acute myeloid leukemia and relapse/refractory multiple myeloma: a therapeutic dilemma

Dewi Nurmaya Spree, Farhan Rafiuddin Jamaluddin, Suria Abd Aziz [...]

Proceedings of Singapore Healthcare

Open accessReview articleFirst published 2020

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

Serena Chew, Melissa C. Mackey, Elias Jabbour

Therapeutic Advances in Hematology

Open accessResearch articleFirst published 2026

Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial

Juan Ren, Tongxin Zhang, Yuqi Wang [...]

Cell Transplantation

Free accessReview articleFirst published June, 2017

Vosaroxin in relapsed/refractory acute myeloid leukemia: efficacy and safety in the context of the current treatment landscape

Valeriy Sedov, Robert K. Stuart

Therapeutic Advances in Hematology

Free accessResearch articleFirst published November, 2018

Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens

Wenfeng Luo, Huilan Yu, Xingli Zou [...]

Cancer Biomarkers

Open accessResearch articleFirst published 2023

Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia

Uday Kulkarni, Arun Kumar Arunachalam, Hamenth Kumar Palani [...]

Cell Transplantation